About: Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.99 (-3.40%)
CVKD NASDAQ Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. Common Stock share price
Atividade de preço de CVKD
Último preço
$ 0,990
Variação (24h)
-0,03 USD (2,93%)
Volume
12.85K
Volume (média 4 sem.)
-
Abertura
$ 1,03
Variação do dia
$ 0,97 - $ 1,07
Fechamento anterior
$ 1,02
Último negócio
22 Oct, 4:27 pm GMT+0
Atrasado
22 Oct, 4:27 pm GMT+0
CVKD price performance
Atrasado
22 Oct, 4:27 pm GMT+0
quote.marketSignals